Top Markets
#1 EXOD EXOD +56.80%
#2 CoW Protocol CoW Protocol +45.22%
#3 Glidr Glidr +45.16%
#4 Cysic Cysic +25.83%
#5 Tutorial Tutorial +24.70%
#6 Walrus Walrus +24.17%
#7 Humanity Humanity +17.87%
#8 Enso Enso +17.09%
#9 Codatta Codatta +14.69%
#10 Huma Finance Huma Finance +14.16%
Coin of the day
EXOD EXOD
Paramètres
Langue
FRANçAIS
Devise
USD
Thème
ASLAN Pharmaceuticals Limited ASLAN Pharmaceuticals Limited

ASLAN Pharmaceuticals Limited

ASLN
Classement en actions #37031
ASLAN Pharmaceuticals Limited is a biopharmaceutical firm operating at the... ASLAN Pharmaceuticals Limited is a biopharmaceutical firm operating at the clinical stage, primarily focused on immunology, and dedicated to creating innovative treatments that profoundly enhance patients' lives. Its advanced therapeutic pipeline features ASLAN004, a monoclonal antibody currently being evaluated for atopic dermatitis and a range of other immunological disorders. Also under development is ASLAN003, a small-molecule inhibitor of dihydroorotate dehydrogenase, intended to treat autoimmune conditions. The company is involved in a joint venture with JAGUAHR Therapeutics Pte. Ltd. and Bukwang Pharmaceutical Co., Ltd., aimed at pioneering immuno-oncology therapeutics that target the AhR pathway. Furthermore, ASLAN maintains partnerships with various entities, including Almirall, Array BioPharma, and CSL Limited. Established in 2010, the company's headquarters are located in Singapore.
Prix de l'action
$0.6
Dernière synchronisation: 2024-08-14
Capitalisation boursière
$2.09M
Changement (1 jour)
0.00%
Changement (1 an)
0.00%
Pays
SG
Échange ASLAN Pharmaceuticals Limited (ASLN)

Catégorie

Healthcare
Ratio P/B pour ASLAN Pharmaceuticals Limited (ASLN)
Ratio P/B au August 2026 TTM : -0.19
Selon les derniers rapports financiers et le cours de l'action de ASLAN Pharmaceuticals Limited, le ratio cours/valeur comptable actuel (TTM) est -0.19. À la fin de 2022, le ratio P/B était de 0.96.
Historique du ratio P/B pour ASLAN Pharmaceuticals Limited de 2014 à 2026
Ratio P/B à la fin de chaque année
Année Ratio P/B Changez
2026 (TTM) -0.19 -11.57%
2023 -0.21 -121.55%
2022 0.96 135.76%
2021 0.41 -118.92%
2020 -2.15 -82.88%
2019 -12.58 -1,216.28%
2018 1.13 -10.51%
2017 1.26 11.69%
2016 1.13 -308.68%
2015 -0.54 496.91%
2014 -0.09 0.00%
Ratio P/B pour des entreprises similaires ou concurrentes
Entreprise Ratio P/B Différence de Ratio P/B Pays
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 6.3419 -3,515.13%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 6.2413 -3,460.96%
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 3.4612 -1,963.87%
BE